| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $12.5M | +224.3% | +434.0% |
| R&D Expense | $154.9M | +12.2% | +100.7% |
| SG&A Expense | $46.3M | +25.7% | +99.1% |
| Operating Income | -$188.8M | -10.3% | -92.4% |
| Net Income | -$174.4M | -10.9% | -117.0% |
| EPS (Basic) | -$1.27 | -5.0% | -95.4% |
| EPS (Diluted) | -$1.27 | -5.0% | -95.4% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $350.2M | +43.6% | -5.4% |
| Current Assets | $1.97B | +57.2% | +21.2% |
| Total Assets | $2.13B | +55.9% | +30.1% |
| Current Liabilities | $169.9M | +25.8% | +86.0% |
| Total Liabilities | $247.9M | +40.7% | +80.5% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$480.7M | — | — |
| Capital Expenditures | $7.8M | — | — |
| Investing Cash Flow | -$245.3M | — | — |
| Financing Cash Flow | $856.1M | — | — |
| Free Cash Flow | -$488.5M | — | — |
| $1.89B |
| +58.2% |
| +25.5% |